Allantoin - Amicus Therapeutics

Drug Profile

Allantoin - Amicus Therapeutics

Alternative Names: SD-101 - Amicus Therapeutics; Zorblisa

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scioderm
  • Developer Amicus Therapeutics
  • Class Anti-inflammatories; Antiacnes; Antipsoriatics; Hydantoins; Imidazolidines; Keratolytics; Small molecules; Urea compounds
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diabetic foot ulcer; Epidermolysis bullosa; Psoriasis

Most Recent Events

  • 13 Sep 2017 Discontinued - Phase-III for Epidermolysis bullosa in Serbia, Belgium, Israel, Lithuania, Spain, Australia, Poland, United Kingdom, Germany, France, Italy, Netherlands and Austria (Topical)
  • 13 Sep 2017 Discontinued - Preclinical for Diabetic foot ulcer in USA (Topical)
  • 13 Sep 2017 Discontinued - Preclinical for Psoriasis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top